Skip to main content
. Author manuscript; available in PMC: 2021 Jul 12.
Published in final edited form as: Med. 2021 Jul 9;2(7):851–863.e3. doi: 10.1016/j.medj.2021.04.011

Figure 4: Liver disease related hazard in UKB cohort stratified by MTARC1 rs264238 and presence of diabetes, obesity and presence of PNPLA3 rs738409:G.

Figure 4:

Liver-related mortality was defined as death due to liver diseases or hepatocellular carcinoma. A) Liver-related mortality in non-obese participants as a function of MTARC1 genotype. B) Liver-related mortality in obese participants as a function of MTARC1 genotype. C) Liver-related mortality in non-diabetic participants as a function of MTARC1 genotype. D) Liver-related mortality in diabetic participants as a function of MTARC1 genotype. E) Liver-related mortality in PNPLA3 rs738409:G non-carriers (genotype C/C) as a function of MTARC1 genotype. D) Liver-related mortality in PNPLA3 rs738409:G-carriers (genotype G/C and G/G) as a function of MTARC1 genotype. Participants were followed prospectively from the time of study entry until death or end of follow-up. Hazard ratios were calculated by Cox regression, adjusted for age, sex, BMI, and PC1-4. HR homozygous vs. non-carriers: A) HR: 0.70 [0.48-1.02], B) HR: 0.52 [0.34-0.80], C) HR: 0.67 [0.49-0.91], D) HR: 0.44 [0.22-0.86], F) HR: 0.43 [0.27-0.71]. HR heterozygous vs. non-carriers: D) HR: 0.59 [0.35-0.81], F) HR:0.76 [0.62-0.94].